2022
Drug Design Strategies: Role of Structural Modifications of Drug Candidates to Improve PK Parameters of New Drugs
NASSAR A. Drug Design Strategies: Role of Structural Modifications of Drug Candidates to Improve PK Parameters of New Drugs. 2022, 323-343. DOI: 10.1002/9781119851042.ch10.Peer-Reviewed Original ResearchDrug candidatesSuccessful drug designDrug metabolism scientistsDrug designDrug discoveryStructural modificationsMetabolic stabilityDiverse propertiesActive metabolitePass metabolismToxicity relationshipsSoft drugsReactive metabolitesInhibition/inductionMetabolism studiesPharmacokinetic issuesRenal clearanceSafe drugPK parametersMetabolic clearanceMetabolic inactivationNew drugsDrugsMetabolitesClearance
2016
Population pharmacokinetic (PK) analysis of laromustine, an emerging alkylating agent, in cancer patients
Nassar AF, Wisnewski AV, King I. Population pharmacokinetic (PK) analysis of laromustine, an emerging alkylating agent, in cancer patients. Xenobiotica 2016, 47: 394-407. PMID: 27440490, DOI: 10.1080/00498254.2016.1201703.Peer-Reviewed Original ResearchConceptsPopulation pharmacokinetic analysisInter-patient variabilityPharmacokinetic analysisSignificant single-agent activitySingle-agent activityPopulation PK analysisVolume of distributionHigh inter-patient variabilityInter-occasion variabilityAlkylating agentCancer patientsTotal clearanceTotal body waterClinical trialsHematologic malignanciesPK analysisDosing cyclesOrgan functionSolid tumorsAntineoplastic alkylating agentCentral compartmentNONMEM analysisRapid clearancePatientsClearance